Syngene International Limited Appoints Vijay Kuchroo as Non-Executive, Independent Director, Effective from March 1, 2017
January 25, 2017 at 06:57 am EST
Share
Syngene International Limited announced that based on the recommendation of Nomination and Remuneration Committee, the Board of Directors at its meeting held on January 24, 2017, has approved the appointment of Dr. Vijay Kuchroo as an Additional Director (Non-Executive, Independent) on Board of the company effective from March 1, 2017 to hold office up to the date of next Annual General Meeting, wherein his appointment as an Independent Director will be placed before the members for their approval. Dr. Vijay K Kuchroo, 61 years, is Senior Scientist at Brigham and Women's Hospital and Co-Director of the Center for Infection and Immunity, Brigham Research Institutes, Boston. He is also an Associate Member of the Broad Institute and a participant in a Klarman Cell Observatory project that focuses on T cell differentiation. He is also the Director of the newly formed Evergrande Centre for Immunologic Diseases at Harvard Medical School and Brigham and Women's Hospital. He is also an Independent, Non-Executive Director on the Board of Biocon Limited. He also serves on the scientific advisory Boards and works in advisory capacity to a number of big pharmaceutical companies including Pfizer, Novartis and Glaxo-Smith-Kline (GSK).
Syngene International Limited is an integrated research, development, and manufacturing services company. The Company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. It offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. SynVent's portfolio covers modalities and therapeutic areas ranging from small molecule inhibitors to targeted protein stabilization. It serves the pharmaceutical, biotechnology, and specialty chemical sectors, among others. It operates multi-modal biologics manufacturing facility.